Can I Take Melatonin with Oral Micronized Progesterone (Prometrium)?

What the Evidence Actually Says About This Combination

Most published interaction databases, including the Natural Medicines Comprehensive Database and the clinical pharmacology module inside Lexicomp, classify the melatonin-progesterone interaction as minor or theoretical. That classification does not mean zero risk. It means the interaction is not expected to produce a clinically meaningful change in drug plasma levels, but additive sedation and the independent metabolic effects of high-dose melatonin still deserve attention.

No prospective randomized controlled trial has enrolled women on OMP and randomized them to melatonin versus placebo to evaluate safety or efficacy outcomes. The evidence base consists of pharmacokinetic studies on each agent separately, mechanistic data on receptor overlap, and observational cohort data.

How Prometrium Is Metabolized

Oral micronized progesterone is absorbed in the gastrointestinal tract and undergoes substantial first-pass hepatic metabolism via CYP3A4 and CYP2C19 enzymes, converting to active metabolites including allopregnanolone and pregnanolone [1]. Peak serum concentrations occur roughly 2 to 3 hours after ingestion. The terminal half-life ranges from 16 to 18 hours, although the sedative metabolites allopregnanolone and pregnanolone clear more rapidly.

A pharmacokinetic study published in Fertility and Sterility confirmed that a single 200 mg bedtime dose of oral micronized progesterone produced mean peak allopregnanolone concentrations of approximately 4 ng/mL at 1 to 2 hours post-dose, with levels returning near baseline by 8 hours [2].

How Melatonin Is Metabolized

Melatonin is primarily metabolized by CYP1A2 in the liver, not CYP3A4 or CYP2C19 [3]. This enzyme-pathway separation is the main reason pharmacokinetic interaction between the two agents is not expected. They do not compete for the same metabolic enzymes. They do not significantly induce or inhibit each other's clearance at typical clinical doses.

Melatonin's half-life is short, approximately 40 to 60 minutes for immediate-release formulations [4]. Exogenous melatonin at 0.5 mg to 5 mg produces peak plasma concentrations within 60 minutes, well ahead of progesterone's 2-to-3-hour peak.

The Sedation Question: Does Combining Both Increase Next-Morning Drowsiness?

Yes, additive sedation is the most clinically relevant concern. Both agents independently promote sleep, through different receptor systems, but the combined sedative burden can be meaningful for some women, particularly those new to OMP.

Progesterone's Sedative Mechanism

Allopregnanolone, the primary active neurosteroid metabolite of progesterone, is a positive allosteric modulator of the GABA-A receptor [5]. This is the same receptor family targeted by benzodiazepines and barbiturates, though allopregnanolone binds at a distinct site. The 100 mg bedtime dose of OMP produces enough allopregnanolone to measurably shorten sleep latency. Many women on Prometrium report noticeable drowsiness within 60 to 90 minutes of their dose, which is why bedtime administration is standard clinical practice.

The PEPI trial (Postmenopausal Estrogen/Progestin Interventions, N=875) did not formally assess subjective sleep, but secondary reports from that cohort noted that women randomized to oral micronized progesterone reported better subjective sleep quality than women on medroxyprogesterone acetate (MPA) [6].

Melatonin's Sedative Mechanism

Melatonin binds MT1 and MT2 receptors in the suprachiasmatic nucleus, shifting circadian phase and reducing core body temperature to initiate sleep [7]. The mechanism is entirely distinct from the GABA-A pathway used by allopregnanolone. Because the two pathways do not converge at the receptor level, pharmacodynamic summation (rather than true combination) is the more accurate description of what happens when both are taken together.

A 2013 Cochrane review of melatonin for sleep disorders (55 randomized trials, N=2,166) found that melatonin decreased sleep onset latency by a mean of 7.06 minutes and increased total sleep time by 8.25 minutes versus placebo [8]. Those are modest effects. Adding melatonin on top of OMP is unlikely to dramatically extend sedation, but residual drowsiness the next morning is a reported patient experience that clinicians should discuss.

Practical Guidance on Timing

Prometrium is standardly taken 30 minutes before bed. Taking melatonin at the same time is common patient behavior. If a woman experiences morning grogginess, shifting melatonin to 60 minutes before Prometrium (rather than concurrently) may reduce peak sedative overlap, since melatonin's plasma half-life is shorter. Dose reduction of melatonin to 0.5 mg to 1 mg is also a reasonable step, since lower doses are frequently as effective as higher doses for sleep onset [9].

Melatonin, Glucose Tolerance, and Women on HRT

This is the more overlooked concern. Melatonin receptors MT1 and MT2 are expressed on pancreatic beta cells, and exogenous melatonin inhibits glucose-stimulated insulin secretion via a cAMP-mediated pathway [10].

What the Clinical Data Show

A randomized crossover trial by Rubio-Sastre et al. (N=16 healthy women) demonstrated that 5 mg of melatonin taken at night significantly impaired oral glucose tolerance the following morning compared with placebo, with post-load glucose 0.46 mmol/L higher after melatonin (P<0.05) [11]. The effect was larger in women carrying the MTNR1B risk allele, a gene variant present in approximately 30% of the general population.

A larger genome-wide association study published in Nature Genetics (N=77,760 individuals) found that higher circulating melatonin levels, linked to MTNR1B variants, associated with increased type 2 diabetes risk [12]. This does not prove that supplemental melatonin causes diabetes, but it establishes that melatonin signaling is not metabolically inert.

Why This Matters for Women on OMP

Oral micronized progesterone at the doses used in HRT (100 to 200 mg nightly) has a generally neutral to mildly favorable metabolic profile compared with synthetic progestins. The PEPI trial found that OMP combined with conjugated equine estrogens did not significantly worsen fasting insulin or glucose compared with estrogen alone [6]. Medroxyprogesterone acetate, by contrast, blunted the HDL-raising benefit of estrogen and showed a less favorable insulin profile.

Adding long-term melatonin at 5 mg or above could theoretically offset some of the metabolic neutrality of OMP, particularly in women who are insulin-resistant or prediabetic at baseline. The clinical significance at doses of 0.5 mg to 1 mg is considered low.

Monitoring Recommendations

Women on OMP who use melatonin regularly (defined as more than 3 nights per week for more than 4 weeks) should have a baseline fasting glucose or HbA1c on file. If melatonin use exceeds 3 mg nightly, repeating fasting glucose at the next annual visit is a reasonable precaution. No current major guideline from the Menopause Society or the Endocrine Society mandates this monitoring specifically for this combination, but the mechanistic rationale supports it.

Pharmacokinetic Interaction: What the Enzyme Data Confirm

The following framework summarizes the metabolic enzyme data for both agents and explains why clinicians classify this as a pharmacodynamic (not pharmacokinetic) interaction.

| Agent | Primary metabolic enzyme | Secondary enzymes | Hepatic extraction | |---|---|---|---| | Oral micronized progesterone | CYP3A4 | CYP2C19 | High (first-pass ~90%) | | Melatonin | CYP1A2 | CYP2C19 (minor) | High (first-pass ~85%) |

CYP2C19 is shared in a minor role by both compounds. In poor metabolizers (roughly 2 to 3% of the European population, up to 15% of East Asian populations), CYP2C19 activity is reduced, meaning both agents could accumulate slightly more than expected [13]. This is not a clinically flagged interaction in any current prescribing information, but women who know they are CYP2C19 poor metabolizers should mention this to their prescriber when adding any supplement metabolized by that pathway.

Melatonin is also a weak inhibitor of CYP1A2 in vitro. Progesterone is not a significant CYP1A2 substrate, so this does not create a bidirectional pharmacokinetic loop between the two agents [14].

What About High-Dose Melatonin?

Over-the-counter melatonin products in the United States frequently contain 5 mg, 10 mg, or even 20 mg per tablet, doses far above what is needed for sleep initiation. A 2023 analysis published in JAMA (Erland and Saxena, supplemented by consumer product testing) found that actual melatonin content in 30 tested products ranged from 74% to 347% of the labeled dose [15]. A woman purchasing a 5 mg tablet may be ingesting up to 17 mg. At those concentrations, the CYP1A2 inhibition in vitro becomes less theoretical and the metabolic effects on insulin secretion become more likely.

The HealthRX clinical recommendation: melatonin 0.5 mg to 1 mg is the dose range with the best evidence for phase-shifting circadian rhythms at menopause and the lowest risk of metabolic or pharmacokinetic concern alongside OMP [9].

Women-Specific Considerations at Menopause

Menopausal women represent the largest group prescribed OMP. Insomnia and sleep disruption affect 40 to 60% of perimenopausal and postmenopausal women, making melatonin a frequently self-selected add-on [16]. Several factors specific to this population influence the risk-benefit calculation.

Endogenous Melatonin Declines with Age

Pineal melatonin production declines significantly after age 40. A study by Zeitzer et al. Found that nocturnal melatonin amplitude was approximately 50% lower in older adults (mean age 67) compared with younger adults (mean age 24) [17]. This biological deficit makes melatonin supplementation conceptually appealing in menopausal women, but it does not eliminate the need to use the lowest effective dose.

Estrogen and Melatonin Interact

Estrogen, frequently co-administered with OMP in standard HRT regimens, upregulates MT1 receptor expression in the suprachiasmatic nucleus. A study in Hormones and Behavior found that estradiol pretreatment enhanced melatonin's phase-shifting effects in ovariectomized rats, suggesting that women on estrogen-containing HRT may be more sensitive to a given melatonin dose than hormone-naive women [18]. Clinically, this means starting at 0.5 mg melatonin rather than 5 mg is especially advisable in women on combined estrogen-progesterone HRT.

Vasomotor Symptoms and Sleep Architecture

Vasomotor symptoms (hot flashes and night sweats) are a primary driver of sleep disruption at menopause. OMP alone does not reliably eliminate vasomotor symptoms; it primarily provides endometrial protection. Melatonin does not address vasomotor symptoms either. Women who add melatonin hoping to resolve hot-flash-related waking may be disappointed and may escalate the dose seeking a response, which increases exposure to higher melatonin concentrations.

The 2023 Menopause Society Position Statement on nonhormonal management of vasomotor symptoms notes that melatonin is not recommended as a treatment for hot flashes due to insufficient evidence [19]. Women seeking relief from night sweats should discuss optimizing their estrogen dose or adding FDA-approved nonhormonal options such as fezolinetant (Veozah, 45 mg daily, FDA-approved May 2023) with their provider.

Special Populations and Contraindications

Hepatic Impairment

Both OMP and melatonin undergo significant first-pass hepatic metabolism. Women with Child-Pugh B or C hepatic impairment should not use OMP per its prescribing information [20]. High-dose melatonin may also accumulate unpredictably in this population. This combination warrants extra caution or avoidance in hepatic disease.

Warfarin Users

Melatonin has been reported to inhibit CYP1A2, which is involved in warfarin (R-warfarin) metabolism. Women taking warfarin alongside OMP (a less common combination, but seen in women with atrial fibrillation or thrombophilia on anticoagulation) should have their INR monitored more closely when melatonin is added or removed from their regimen [14].

Autoimmune Conditions

Melatonin has immunomodulatory properties and at pharmacological doses may stimulate certain immune pathways. Women with autoimmune conditions such as lupus or rheumatoid arthritis should discuss melatonin use with their rheumatologist before starting, independent of OMP use.

What to Tell Your Prescriber

Open communication between patient and provider is the most direct risk-reduction strategy. Women should report all supplements, including melatonin, at every HRT follow-up visit. The FDA's MedWatch system records adverse events from supplement-drug combinations, but under-reporting is significant [21].

If you are currently taking both melatonin and OMP, the following checklist is clinically relevant.

• Report the melatonin dose accurately. Check the label and, when possible, choose brands third-party tested by NSF International or USP.
• If morning drowsiness is a problem, try reducing melatonin to 0.5 mg before changing your OMP dose.
• If you have prediabetes, metabolic syndrome, or a first-degree relative with type 2 diabetes, ask your provider whether a fasting glucose check at your next visit is warranted.
• If you use warfarin, request an INR check within 2 to 4 weeks of starting or stopping melatonin.
• If you feel no benefit from melatonin after 2 to 4 weeks at a low dose, discontinue rather than escalate.

The Menopause Society's 2022 Hormone Therapy Position Statement states: "Women should be counseled that OTC supplements used concurrently with hormone therapy may carry additive or independent physiological effects that have not been evaluated in randomized trials." [22]